Compare TRTX & SCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRTX | SCTX |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 660.2M | 536.5M |
| IPO Year | 2015 | 2026 |
| Metric | TRTX | SCTX |
|---|---|---|
| Price | $7.78 | $31.63 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $9.83 | N/A |
| AVG Volume (30 Days) | ★ 773.7K | 215.2K |
| Earning Date | 04-28-2026 | N/A |
| Dividend Yield | ★ 11.55% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.78 | N/A |
| Revenue Next Year | $4.14 | N/A |
| P/E Ratio | $41.05 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.57 | $17.31 |
| 52 Week High | $9.85 | $39.60 |
| Indicator | TRTX | SCTX |
|---|---|---|
| Relative Strength Index (RSI) | 45.60 | 58.65 |
| Support Level | $7.57 | $27.20 |
| Resistance Level | $8.74 | $39.60 |
| Average True Range (ATR) | 0.12 | 4.63 |
| MACD | 0.02 | -0.06 |
| Stochastic Oscillator | 51.28 | 58.48 |
TPG RE Finance Trust Inc is a commercial real estate finance company. It originates, acquires, and manages commercial mortgage loans and other commercial real estate-related debt instruments consisting of first mortgage loans and senior participation interests in first mortgage loans secured by institutional-quality properties in primary and select secondary markets in the United States. The company's objective is to provide attractive risk-adjusted returns to its stockholders over time through cash distributions and capital appreciation. It focuses on directly originating and selectively acquiring floating-rate first mortgage loans that are secured by high-quality commercial real estate properties undergoing some form of transition and value creation.
Scribe Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of in vivo CRISPR-based genetic medicines. Its research and development activities focus on cardiovascular and metabolic diseases, including atherosclerotic cardiovascular disease (ASCVD). The company's product pipeline includes STX-1150, a CRISPR-based product candidate that utilizes its ELXR epigenetic silencing technology.